Results 131 to 140 of about 139,343 (219)

Author Correction: Muskelin is a substrate adaptor of the highly regulated Drosophila embryonic CTLH E3 ligase. [PDF]

EMBO Rep
Briney CA, Henriksen JC, Lin C, Jones LA, Benner L, Rains AB, Gutierrez R, Gafken PR, Rissland OS.   +8 more
europepmc   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

conMItion: an R package adjusting confounding factors for associations in multi-omics. [PDF]

Bioinformatics
Wang G, Liu F, Chen Z, Davoli T.
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languages. [PDF]

J Med Genet
De Nicolo A, Eccles DM, Aaltonen K, Alhopuro P, Ariansen SL, Biancolella M, Caputo SM, Caron O, Cavalli P, Chiang J, Claes KBM, Cuaresma ECS, de la Hoya M, De Pauw A, Díez O, Domínguez-Valentin M, Ehrencrona H, Fjeldvær MK, Fostira F, Francia MBD, Galego-Carro J, Gómez García EB, Hassan NT, Hauke J, Hirasawa A, Huang X, Ilagan-Cargullo EMH, Imoto I, Jonnagadla S, Karthikeyan M, Kleiblova P, Konstantopoulou I, Kowalik A, Kvist A, Lesueur F, Li ST, López-Fernández A, Machackova E, Martins A, Mensenkamp AR, Momozawa Y, Montalban G, Monteiro ANA, Nevanlinna H, Ngeow J, Palmero EI, Pedersen IS, Que FVF, Santamariña M, Santana Dos Santos E, Singer CF, Siołek M, Solano AR, Soukupova J, Suresh PD, Szczepaniak M, Tan YY, Teo SH, Tham E, Thomassen M, Tsaousis G, Hansen TVO, Vega A, Velasco-Sampedro EA, Wangensteen T, Wappenschmidt B, Yannoukakos D, Yoon SY, Spurdle AB, Radice P.   +69 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Narratives of contingency as historical evidence for philosophical arguments of contingency: pathway decisions in the early development of molecular genetics. [PDF]

Hist Philos Life Sci
de Cock W.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Correction: Mesoangioblasts at 20: from the embryonic aorta to the patient bed. [PDF]

Front Genet
Cossu G, Tonlorenzi R, Brunelli S, Sampaolesi M, Messina G, Azzoni E, Benedetti S, Biressi S, Bonfanti C, Bragg L, Camps J, Cappellari O, Cassano M, Ciceri F, Coletta M, Covarello D, Crippa S, Cusella-De Angelis MG, De Angelis L, Dellavalle A, Diaz-Manera J, Fancello I, Galli D, Galli F, Gargioli C, Gerli MFM, Giacomazzi G, Galvez BG, Hoshiya H, Guttinger M, Innocenzi A, Minasi MG, Perani L, Previtali SC, Quattrocelli M, Ragazzi M, Roostalu U, Rossi G, Santoleri S, Scardigli R, Sirabella D, Tedesco FS, Torrente Y, Ugarte G.   +43 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source